Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    ClinicalTrials.gov updated the page’s revision/build indicator from v3.5.2 to v3.5.3, reflecting a site version change rather than any changes to the study record.
    Difference
    0.1%
    Check dated 2026-04-24T22:23:42.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T13:59:10.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    46 days ago
    Change Detected
    Summary
    Site revision history shows an addition of v3.5.0 and a deletion of v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-19T23:30:45.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T20:21:19.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The study record shows new update dates (2026-02-12, 2026-02-17, 2026-08-15) and the field 'Product Manufactured in and Exported from the U.S.' has been removed.
    Difference
    0.5%
    Check dated 2026-02-19T04:52:51.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T02:23:50.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.